# Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

> **NCT00060476** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 15000 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** rofecoxib
- **DRUG:** Comparator: placebo (unspecified)

## Key facts

- **NCT ID:** NCT00060476
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01-08
- **Primary completion:** 2004-12-08
- **Final completion:** 2004-12-08
- **Target enrollment:** 15000 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060476, "Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00060476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*